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ABSTRACT
The crustacean Artemia franciscana has been used as a drug carrier, mainly in its nauplius stage; however, the 
use of other developmental stages, i.e., metanauplius, juvenile, and adult, potentially allows treating diseases not 
only in fry but also in juveniles and adults. In the present work, we studied the incorporation of antibiotics in these 
stages to inhibit the growth of the bacterium Aeromonas hydrophila, which causes a high mortality in freshwater 
fishes. The antibiotics used were: chloramphenicol (base antibiotic), nitrofurantoin (Macrodantina®, 50 mg capsules) 
and ciprofloxacin (Ciproflox®, 250 mg capsules). Four wells were made in Petri dishes with Trypticase® soybean 
agar (TSA) and 2 mL of bacterial inoculum. The wells were used for each antibiotic and one for the control. A 1-
mL sample of each Artemia stage, incorporated with an antibiotic, was placed in each well and incubated for 24 h 
at 37°C, measuring the inhibition halos thereafter. Results indicated that 4 h are needed for the nauplii to become 
saturated and for the metanauplii, juveniles, and adults to fill their digestive tract with the antibiotic. In nauplii, the 
three antibiotics produced inhibition halos; in metanauplii, ciprofloxacin produced the best result (22.57 mm); in 
juveniles, chloramphenicol (38 mm) and ciprofloxacin (33 mm) gave the best results; in adults, the best results were 
obtained also with chloramphenicol (33 mm) and ciprofloxacin (40 mm). Nitrofurantoin did not yield positive results in 
metanauplii, juveniles, and adults, and because it is soluble in water, it is recommended to apply it in lipidic solutions 
to ease its incorporation. Results from this study allow us to establish the bases for the control and treatment of 
infectious diseases caused by the bacterium Aeromonas hydrophila through the use of commercial antibiotics, easily 
available in Mexico. 
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INTRODUCTION
Chemotherapeutics directly applied to the water or admi-
nistered through the feed are generally used in aquaculture to 
treat infectious diseases. In this two ways of application, part 
of the drug is lost in the water, inducing a pollution problem and, 
besides, the organism does not consume the adequate dose 
(Gapasin et al., 1996). Therefore, it has been necessary to find 
alternative ways to provide medication in this field. 
It is important to develop methodologies that will allow 
using live feed as a carrier, not only of enriching substances 
but also of prophylactic and therapeutic substances, because, 
through this mechanism, treatment is not lost in the water and is 
more efficient as it is not dissolved (Mohney et al., 1990; Chérel 
& Nin, 1991), and allows the administration of the adequate dose 
needed by each species and in each developmental stage.
The crustacean Artemia franciscana (Kellogg, 1906) has 
been traditionally used as a drug carrier (Mohney et al., 1990; 
Nelis et al., 1991; Verpraet et al., 1992; Aguilar-Aguila et al., 
1994; Dixon et al., 1995a,b; Touraki et al., 1996, 1999; Majack 
et al., 2000; Gómez-Gil et al., 2001; Cook & Rust, 2002) mainly 
in its nauplius stage because of its availability, easy handling, 
and small size. This stage is used as feed for diverse species 
in culture (Castro et al., 2003); however, using Artemia in other 
developmental stages, such as metanauplii, juveniles, and adults 
will allow treating infectious diseases not only in fish fry but also 
in juveniles and adults, even in brood stock, avoiding in this way 
the horizontal and vertical transmission of the pathogen, and the 
consequent economical losses due to mortality of organisms in 
culture caused by viruses, bacteria, fungi, and parasites. 
The pathogenic bacterium Aeromonas hydrophila (Stainer, 
1943) can cause high mortality in culture systems, inducing 
morphological and physiological changes in the organisms and, 
consequently, strong economical losses to aquaculture farmers 
(Trust, 1986; Alderman, 1988; Alderman & Hastings, 1998). Based 
on the after mentioned, the aim of this work was to investigate 
whether bioencapsulation of three different antibiotics in nauplii, 
metanauplii, juveniles, and adults of A. franciscana presented 
activity against A. hydrophyla. 
MATERIAL AND METHODS
Culture of A. franciscana. Organisms were cultured until the adult 
stage in three 200 L cylindrical, plastic containers, maintaining a 
salinity of 60 g/L and constant aeration. A one organism/mL den-
sity was kept in each container. Organisms were fed daily with 
50 mL of a rice bran preparation during the first five days of life 
and thereafter with two liters of Tetraselmis spp. and Chlorella 
spp. at a relation of 1:1, until reaching the adult stage, which, by 
reproducing, provided the metanauplius and juvenile stages. 
For the nauplii, we followed the decapsulation technique des-
cribed by Sorgeloos et al. (1986) and modified by Castro and De 
Lara (1991). The eggs, without the chorion, where placed in a 3-L 
RESUMEN
El crustáceo Artemia franciscana se ha utilizado como transportador de medicamentos, principalmente en su 
estadio de nauplio; sin embargo, el uso de otros estadios de desarrollo, como por ejemplo, metanauplio, juvenil y 
adulto, ha permitido el tratamiento contra las enfermedades, no sólo en larvas, sino en juveniles y adultos. En el 
presente trabajo, se incorporaron antibióticos en estos estadios para inhibir el crecimiento de la bacteria Aeromonas 
hydrophila, que causa altas mortalidades en peces de agua dulce. Los antibióticos probados fueron: cloramfenicol 
(base pura), nitrofurantoina (Macrodantina®, cápsulas de 50 mg) y ciprofloxacina (Ciproflox®, cápsula de 250 mg). 
En cajas de Petri con un medio de agar de soya Triptocaseína (TSA) y 2 ml de inóculo de la bacteria se hicieron 
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de cada estadio de Artemia con antibiótico incorporado, se colocaron en cada pozo y se incubaron por 24 h a 37 °C, 
y se midieron los halos de inhibición. Los resultados indican que se necesitan 4 h para que el nauplio se sature y los 
metanauplios, juveniles y adultos llenen su tracto digestivo con el antibiótico. En los nauplios, los tres antibióticos 
produjeron halos de inhibición; en los metanauplios, el ciprofloxacino dio los mejores resultados (22.57 mm); en 
juveniles, el cloramfenicol (38 mm) y el ciprofloxacino (33 mm) dieron los mejores resultados; en adultos, los mejores 
resultados se obtuvieron con cloramfenicol (33 mm) y ciprofloxacino (40 mm). La nitrofurantoina no dio resultados 
positivos en metanauplios, juveniles y adultos, debido a que es soluble en el agua, se recomienda aplicarlo en 
soluciones lipídicas para facilitar su incorporación. Los resultados de este estudio, nos permiten establecer las 
bases para el control y tratamiento de enfermedades infecciosas causadas por la bacteria Aeromonas hydrophila, 
usando antibióticos comerciales de fácil adquisición en México.
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glass container provided with 3 L water at a salinity of 40 g/L, and 
constant aeration and controlled temperature (23 ± 2°C).
Culture of the bacterial strain. The bacterium used in this work 
was Aeromonas hydrophila (strain ATCC 7966, provided by 
the School of Chemistry, UNAM). The bacterial strain was kept 
refrigerated at -20°C, until used. When needed, it was thawed 
by keeping it at ambient temperature for 24 h to verify viability 
it was placed in a liquid Trypticase® soybean (TSB Bioxon, 
Mexico) medium and incubated for 24 h at 37°C according to 
Gherna’s technique (1994). Bacterial mobility was verified with 
a microscope. 
Antibiotics. We performed an antibiogram with 39 antibiotics 
that inhibit Aeromonas growth, from these we chose three that 
gave a larger than 10 mm inhibition halo, independently from the 
sanitary regulation of Food and Drug Administration (FDA) enfor-
ced in aquaculture. The three chosen antibiotics, either in their 
base form (pure) or in capsules were: chloramphenicol (base 
antibiotic), nitrofurantoin (Macrodantina®, 50 mg capsules), and 
ciprofloxacin (Ciproflox®, 250 mg capsules).
Standard calibration curve of the antibiotic vs. the inhibitory 
halo. For each antibiotic, a calibration curve was performed to 
determine the relation between the diameter of the inhibition 
halo and the antibiotic concentration. This relation was used to 
calculate the appropriate amount of antibiotic to be incorporated 
during the different developmental stages of A. franciscana. 
To obtain the calibration curve of the antibiotic concentration, 
sensidisks of 6 mm in diameter were used, one for each antibiotic 
(chloramphenicol, 30 µg; nitrofurantoin, 300 µg; ciprofloxacin, 5 
µg). Sensidisks were cut in half, and one of the halves was cut 
anew in half to obtain three parts, then each part was weighed 
on an analytical-grade scale (Dr. H. Sandoval, 2003. Personal 
communication). To obtain the inhibition halos of each part of the 
sensidisk, the three parts were placed in Petri dishes containing 
a Trypticase® soybean agar (TSA) medium and 2 mL of the bac-
terial broth. Petri dishes were incubated for 24 h at 37°C and the 
inhibition halo was measured with a micrometer (Vernier). This 
was done in triplicate. 
The calibration curve was done based on the concentration 
value in each part of the sensidisk and contrasting it against the 
inhibition halo area. The linear regression between these two 
values was expressed with the equation:
y (concentration) = a x (inhibition area) + b
where the value of a is the slope of the curve and b is the inter-
ception. To avoid errors in data, by means of the Excel® software 
the straight line to the interception was taken to the zero value. 
Estimation of antibiotic concentrations obtained in each bioassay 
was achieved according to the equation. 
All the work from there on was performed under sterile conditio-
ns, using sterilized materials.
Incorporation time of antibiotics in A. franciscana. To determine 
the antibiotics incorporation into the digestive tract of Artemia, 
with a 90% survival, the concentrations of each antibiotic varied 
and the amounts chosen were: 1 g of chloramphenicol, 250 mg 
of cyprofloxacin (one capsule), and 100 mg of nitrofurantoin (2 
capsules); each antibiotic concentration was dissolved in 500 
mL of water at 40 g/L salinity, and was then filtered through a 53 
µm mesh to obtain the size needed for its ingestion by Artemia 
(Gelabert, 2003). To each antibiotic solution, 1,000 metanauplii, 
100 juveniles, and 100 adults were added separately. Organisms 
were observed under the microscope every 20 min to determine 
the time needed to fill the digestive tract with the antibiotic in 
more than 90% of them. Considering that nauplii are unable to 
ingest particles because their digestive tract is still closed, they 
were left in the solution until their bodies became impregnated 
with the drug, since nauplii can only ingest particles 8 h after 
eclosion, when their mouth and digestive tract have oponed 
(Coutteau & Sorgeloos, 1997).
Drug incorporation bioassays during the different A. franciscana 
developmental stages.
Nauplii and metanauplii. A total of 5,000 nauplii (10 organisms/
mL) was placed in a 500-mL flask with water at 40 g/L salinity, 
ambient temperature (23 ± 2°C), and constant aeration. This 
procedure was followed with each antibiotic. The antibiotic, at 
the previously indicated concentration, was added to each flask. 
Once the nauplii became impregnated with the drug, they were 
filtered and washed with freshwater and then manually ground 
in a mortar. 
In 10 cm diameter Petri dishes with 50 mL TSA medium and 2 mL 
of bacterial inoculum, four small wells (1.0 X 0.5 cm or 1.5-6 mL) 
were made, one for each antibiotic and one for the witness. 1 mL 
of the ground nauplii was placed in each well. The Petri dishes 
were incubated for 24 h at 37°C, and the inhibition halos were 
measured.
For the metanauplii bioassay, 48 h old organisms were 
used; they were placed in the solution with the specific drug 
and left until at least 90% of them showed a full digestive tract. 
Procedures to determine incorporation of the antibiotic, and its 
effects were the same as for nauplii. 
Juveniles and adults. To perform the bioassays with these two 
developmental stages, 200 juvenile organisms (10 days old) and 
200 adults (15 days old) were removed from the culture. Each 
group was placed in 1-L flasks containing 500 mL of water at 
40 g/L salinity; this was done for each antibiotic. Organisms 
were left 24 h without any feed, afterwards these stages were 
incorporated into the solutions containing each of the anti-
biotics at the mentioned concentrations. The organisms were 
observed through a microscope until 90% had a full digestive 
tract, then they were removed from the solution and washed 
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with freshwater. Because juveniles and adults have sizes 300 to 
500-times larger than nauplii and metanauplii we made groups 
of 5, 10, 15, 25, 50 individuals, as well as a control group of 50 
individuals. Each group was placed in a mortar and manually 
ground. To determine the inhibition halo in these developmental 
stages the same technique used for nauplii and metanauplii was 
followed. 
Statistical analysis. To make the antibiotics calibration curve all 
data were subjected to linear regression aimed at obtaining the 
relation between the inhibition halo diameter and the antibiotic 
concentration. The standard curve was made in triplicate.
RESULTS
Antibiotics calibration curves. Table 1 shows the results from 
the determination of inhibition of the three chosen antibiotics 
considering the size of the sensidisk (1, ½, and ¼). The relation 
between the concentration of each antibiotic and the inhibition 
area is expressed as:
Y = 3.1912X+5E-14 for chloramphenicol (R2 = 0.9944)
Y = 24.517X+2E-13 for ciprofloxacin (R2 = 0.9616)
Y= 0.2832X-6E-14 for nitrofurantoin (R2 = 0.9944).
With these formulas, we calculated the concentration 
reached by each antibiotic incorporated into the A. franciscana 
nauplii, metanauplii, juveniles, and adults. 
Antibiotics incorporation time into A. franciscana. In each 
of the developmental stages, the digestive tract became full in 
3:30 to 4:00 h. No differences were observed in the filling time 
with any of the three antibiotics among the different develop-
mental stages. 
Incorporation bioassays during the different A. franciscana 
developmental stages 
Nauplii. Results are shown in Table 2. The antibiotic with the 
largest inhibition halo was nitrofurantoin with an average value 
of 22.27 mm, yielding a concentration of 1,375.42 µg/mL. The other 
two antibiotics presented inhibition halos larger than 10 mm. 
Metanauplii. Results are shown in Table 3. The antibiotic with the 
largest inhibition halo was ciprofloxacin with an average value of 
22.57±0.49 mm yielding a concentration of 16.32 µg/mL, followed 
by chloramphenicol with 15.40 ± 2.90 mm; nitrofurantoin did not 
form an inhibition halo. 
Juveniles. The bioassay in this stage was performed with 25 indi-
viduals for each antibiotic. Chloramphenicol and ciprofloxacin 
produced inhibition halos of 38 and 33 mm, respectively (355.39 
µg/mL and 34.89 µg/mL). Nitrofurantoin did not form an inhibition 
halo (Table 4). 
Adults. Table 5 shows the diameters of the inhibition halos obtai-
ned with the three antibiotics in the different A. franciscana 
groups. With chloramphenicol and ciprofloxacin an increase in 
the diameter of the inhibition halo was observed concomitantly 
with the increase in the amount of organisms, obtaining values 
from 26 to 33 mm for chloramphenicol (170.62 a 262.68 µg/mL) and 
29 to 40 mm for ciprofloxacin (27.56 a 50.41 µg/mL). Nitrofurantoin 
showed no inhibition halo. 
DISCUSSION
Aeromonas hydrophila used did not show sensitivity to 
36 of the 39 antibiotics specific for the inhibition of Aeromonas 
growth. Therefore, we chose chloramphenicol, ciprofloxacin, 
and nitrofurantoin that gave larger than 10-mm inhitibion halos, 
although two of these products do not comply with the sanitary 




Diameter of the 
inhibition halo 
(mm)






Chloramphenicol 1 0.00860 11.2 98.52 30.0
½ 0.00238 6.8 36.32 8.3
¼ 0.00100 6.3 31.17 3.5
Ciprofloxacin 1 0.00661 12.7 126.68 5.0
½ 0.00233 10.2 81.71 1.8
¼ 0.00190 6.6 34.73 1.4
Nitrofurantoin 1 0.00858 10.0 79.33 300.0
½ 0.00360 9.1 65.04 125.9
¼ 0.00292 6.2 41.28 102.1
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regulation for their use in aquaculture, and the other is only 
recommended for human use (Hernandez, 2005) but they are 
easy to obtain in the pharmaceutical market in Mexico and their 
presentation in capsules eases their handling. 
There is scarce bibliographic information on the use of 
these antibiotics being incorporated into A. franciscana, during 
its different developmental stages. For example, Léger and 
Sorgeloos (1992) used chloramphenicol in A. franciscana nau-
plii, enriching them during 6 h with a lipidic solution (SELCO); 
but there are no references to ciprofloxacin and nitrofurantoin 
incorporation in this developmental stage nor on their use in 
metanauplii and juveniles. In the adult stage, Dixon et al. (1995b) 
incorporated the antibiotic sarafloxacin, and Majack et al. (2000), 
Cook and Rust (2002), and Cook et al. (2003) used the antibiotic 
erythromycin, in three different chemical forms, obtaining a 75% 
survival in adults at a 67-79 µg/L concentration. 
The technique used in this work to determine the relation 
between the inhibition area and the antibiotic concentration 
differs from the techniques described by Roque et al. (1998), 
Mohney et al. (1990), Majack et al. (2000), Gómez-Gil et al. (2001), 
and Cook et al. (2003). These authors performed dilutions of the 
antibiotics concentration, considering their known value, and 
used the plate diffusion technique to determine the inhibition 
areas. In the present work, a modification was performed to the 
plate diffusion technique, which consisted in using fractions of 
the sensidisks to determine the inhibition area; therefore, no 
proportion was observed in the diameter of the inhibition halo 
with respect to the antibiotic concentration. The obtained data 
allowed us to perform a regression that gave a correlation of R2 
= 0.9 for the three antibiotics; hence, a linear response of the inhi-
bition halo against the antibiotic concentration. Aguilar-Aguila 
et al. (1994) recorded a correlation value of R2 = 0.81 between 
the concentration of the antibiotic Romet-30 (trimethoprim + 
sulfamethoxazole) and the obtained inhibition area, using plate 
diffusion tests. 
In this research we determined that a period of 4 h is more 
than enough to fill the digestive tract of more than 90% of A. fran-
ciscana metanauplii, juveniles, and adults, and to impregnate 
the body of the nauplii with chloramphenicol, and ciprofloxacin. 
Regarding nitrofurantoin, this yielded positive values only in the 
nauplii stage. Other authors, like Touraki et al. (1991; 1996), have 
indicated that the incorporation time in nauplii can vary from 1 to 















Chloramphenicol 18.0 17.2 17.5 17.57±0.40 242.46 75.98
Ciprofloxacin 10.0 13.5 7.5 10.33±3.01 83.81 3.42
Nitrofurantoin 22.7 22.3 21.8 22.27±0.39 389.52 1,375.42













Area of the 




Chloramphenicol 12.4 15.6 18.2 15.40 ±2.90 186.26 58.37
Ciprofloxacin 22.0 22.9 22.8 22.57 ±0.49 400.09 16.32
Nitrofurantoin N.D. N.D. N.D. N.D. N.D. N.D.
N.D. = Not detected
Table 4. Inhibition halos produced by the three antibiotics in juveniles.
Antibiotic
Diameter of the 
inhibition halo 
(mm)





Chloramphenicol 38.0 1,134.12 355.39
Ciprofloxacin 33.0 855.30 34.89
Nitrofurantoin N.D. N.D. N.D.
N.D. = Not detected
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8 h, depending on the substance being bioencapsulated. Dixon 
et al. (1995b) incorporated the antibiotic sarafloxacin at 10% + 
SELCO in a 6-h period; Mohney et al. (1990) and Touraki et al. 
(1999) incorporated Romet-30 (80% sulfadimethoxazole and 20% 
omethoprim) in a 4 h period; and Gómez-Gil et al. (2001) incorpo-
rated the antibiotic enrofloxacin in 4 h.
Regarding antibiotic incorporation in the adult stage, Majack 
et al. (2000), and Cook and Rust (2002) indicated that addition of 
the antibiotic erythromycin during periods of 14 until 18 h at a 
maximum induces a high mortality starting at 8 hours. Majack et 
al. (2000), using a 2.0 g/L erythromycin suspension, reached the 
maximal concentration in adult organisms in just 2 h. 
Nauplii. The three antibiotics adhered to the nauplius and, 
hence, showed inhibition halos against the A. hydrophila bacte-
rium. It is important to point out that this stage is the most used as 
drug carrier because of its easy handling. This might be a more 
realistic application approach, mainly because nauplii are used 
as feed for some larval stages of economically important fishes 
in Mexico.
Metanauplii. In contrast to the nauplius, in this stage the diges-
tive tract is already complete and is able to incorporate small 
particles. Gelabert (2003) indicates that in small A. franciscana 
(0.8 to 3.2 mm) organisms, the particles filtration process is more 
efficient than in later stages; Wilson (1989) states that the intense 
metabolic activity during this stage fosters the filtration activity. 
This behavior was observed when the antibiotics chloramphe-
nicol and ciprofloxacin were given, as these are not completely 
soluble and their particles were assimilated by metanauplii that 
gave inhibition halos, whereas nitrofurantoin, which is soluble, 
did not induce an inhibition halo. 
Juveniles and adults. In these two stages, the morphological 
development of the organisms is complete; the thoracic appen-
dages (thoracopods) play an important role in particles filtration, 
so that if the antibiotic is soluble, like nitrofurantoin, it does not 
incorporate easily into the organism, and therefore no inhibitory 
effect on the bacterium is manifested. As in metanauplii, the 
antibiotics chloramphenicol and ciprofloxacin yielded large 
inhibitory halos in these two developmental stages resulting from 
their retention in the organism’s body. 
When working with antibiotics, it is necessary to know the 
maximal amount tolerated by the carrier organism, in this case 
A. franciscana, to be able to recommend an adequate dose. 
When using the antibiotics chloramphenicol (base antibiotic) 
and ciprofloxacin (Ciproflox®, 250 mg capsules), commercial 
presentation, it is recommended to make 50% dilutions, because 
the commercial doses were not tolerated by this species, pre-
senting a high mortality at 4 h of bioencapsulation. The antibiotic 
nitrofurantoin (Macrodantina, 50 mg capsules), although having 
effects in Artemia nauplii, did not yield positive results in the 
metanauplii, juvenile, and adult stages, hence it must be tested 
at higher doses or the drug must be emulsified. 
Although further research on the incorporation of drugs in 
more advanced developmental stages of A. franciscana is still 
needed, this study provides original and practical information 
Table 5. Inhibition halos produced by the three antibiotics in adults.
Groups (No. of organisms)
5 10 15 25 50
Antibiotic
Chloramphenicol 18 20 21 23 24
33 37 38 38 39
28 31 32 33 35
Mean ±SD 26.33 ±7.64 29.33 ±8.62 30.33 ±8.62 31.33 ±7.64 32.67 ±7.77
Area of the inhibition halo (mm2) 544.49 675.64 722.50 770.92 838.28
Concentration of the antibiotic (µg/mL) 170.62 211.72 226.4 241.58 262.68
Ciprofloxacin 20 23 25 32 34
37 39 40 43 43
31 34 36 40 42
Mean ±SD 29.33 ±8.62 32.00 ±8.19 33.67 ±7.77 38.33 ±5.69 39.67 ±4.93
Area of the inhibition  halo (mm2) 675.64 804.25 890.38 1,153.90 1,235.99
Concentration of the antibiotic   (µg/mL) 27.56 32.80 36.32 47.07 50.41
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that can be used in aquaculture activities, specifically for the 
prevention and treatment of diseases caused by the bacterium A. 
hydrophila, as well as on the use of easily available commercial 
antibiotics. 
Although the objective of the present work was fulfilled, as 
we determined the incorporation time of the studied antibiotics 
into the different developmental stages of Artemia, as well as 
their survival and the effect on the Aeromonas hydrophila bac-
terium; we consider that it will be necessary to test other anti-
biotics recommended by FDA to be used in aquaculture and to 
assess the feasibility of the technique used in the present work. 
REFERENCES
AguilAr-AguilA, A., A. TejedA-MAnsir & A. ruiz-enríquez. 1994. 
Using brine shrimp as a drug carrier for therapeutic applications in 
aquaculture. Aquaculture Engineering 13: 301-309.
AlderMAn, d.j. 1988. Fisheries chemotherapy a review. In: Muir, J.F. & 
R.J. Roberts (Eds.). Recent Advances in Aquaculture. Vol. 3. Croom 
Helm. London, United Kingdom and Timber Press, Portland, Oregon, 
pp. 1-61.
AlderMAn, d.j. & T.s. HAsTings. 1998. Antibiotic use in aquaculture: 
development on antibiotic resistance-potential for consumer health 
risks. Journal of Food Science Technology 33: 139-155.
CAsTro, B.T., M.j. CAsTro & M.g. CAsTro. 2003. Artemia. In: B.T. 
Castro (Ed.). Alimento vivo para organismos acuáticos. AGT Editor, 
S.A. México. pp. 67-81.
CAsTro, M.j. & de lArA, A.r. 1991. Manual de técnicas para el manejo 
de quistes de Artemia sp. Manual. CBS: Universidad Autónoma 
Metropolitana-Xochimilco. 47 p.
CHerel, P. & F. nin. 1991. Antibiotherapy using biocarriers (Artemia 
salina) in hatcheries. In: Chemotherapy in Aquaculture: from theory 
to reality. Ed. British Crown. pp. 389-393.
Cook M.A. & M.B. rusT. 2002. Bioencapsulation of five forms of 
erythromycin by adult Artemia salina (L.). Journal of Fish Diseases 
25: 165-170.
Cook, M.A., M.B. rusT, k. Messee, T. MAjACk & M.e. PeTerson. 
2003. Uptake of erythromycin by first-feeding sockeye salmon, 
Oncorhynchus nerka (Walbaum), feed live or freeze-dried enriched 
adult Artemia or medicated pellets. Journal of Fish Disease 26: 
277-285.
CouTTeAu, P. & P. sorgeloos. 1997. Manipulation of dietary lipids, fatty 
acids and vitamins in zooplankton cultures. Freshwater Biology 38: 
501-512.
dixon, B.A., s.o. VAn PouCke, d. kAwAHigAsHi, M. CHAir, M. 
deHAsque, H.j. nelis, P. sorgeloos & A.P. de leenHeer. 1995A. 
In: P. Lavens, E. Jaspers y I. Roelants (Eds.). Bioencapsulation 
of antibacterial drugs in nauplii and adult brine shrimp, Artemia 
franciscana. Larvi 95. Fish & Shellfish Larviculture Symposium. 
European Aquaculture Society. Special Publications. No. 24. Genth, 
Belgium, pp. 508-510.
dixon, B.A., s.o. VAn PouCke, M. CHAir, M. deHAsque, H.j. nelis, 
P. sorgeloos & A.P. de leenHeer. 1995B. Bioencapsulation of 
the antibacterial drug sarafloxacin in naupliii of the brine shrimp 
Artemia franciscana. Journal of Aquatic Animal Health 7: 42-45.
gAPAsin, r.s.j., H.j. nelis, M. CHAir & P. sorgeloos. 1996. Drug assi-
milation in the tissue of European sea bass (Dicentrarchus labrax) 
fry delivered orally through bioencapsulation. Journal of Applied 
Ichtyology 12: 39-42.
gelABerT, F. r. 2003. Bioencapsulation in Artemia: II. Influences of 
the particle concentration in the enrichment process. Aquaculture 
216:143-153.
gHernA, r.l. 1994. Culture preservation. In: P. Gerhardt, R. G. E. Murray, 
W. A. Wood & N. R. Krieg (Eds.). Methods for General and Molecular 
Bacteriology, pp. 278–292. American Society Microbiology. 
Washington, DC. 278-290
góMez-gil, B., j. CABAnillAs-rAMos, s. PAez-BrAMBillA & A. roque. 
2001. Standardization of the bioencapsulation of enrofloxacin and 
oxytetracycline in Artemia franciscana Kellogg, 1906. Aquaculture 
196:1-12.
HernAndez, s.P. 2005. Responsible use of antibiotics in aquaculture. 
FAO Fisheries Technical Paper. No. 469. Rome. 97 p.
léger, P. & P. sorgeloos. 1992. Optimized feeding regimes in shrimp 
hatchery. In: A.W. Fast & L.J. Lester (Eds.) Marine shrimp culture: 
principles and practices. Chapter 9. Elsevier Science Publishers. 
U.S.A. pp. 225-244.
MAjACk, T.j., M.B. rusT, k.C. MAssee, g.w. kissil, r.w. HArdy & 
M.e. PeTerson. 2000. Bioencapsulation of erythromycin using 
adult brine shrimp, Artemia franciscana (Latreille). Journal of Fish 
Disease 23: 71-76.
MoHney, l., d. ligHTner & r. williAMs. 1990. Bioencapsulation of 
therapeutic quantities of the antibacterial Romet-30 in nauplii of the 
Brine shrimp Artemia and in the Nematode Panagrellus redivivus. 
Journal of the World Aquaculture Society 21(3): 186-191.
nelis, H.j., F.leger, P. sorgeloos & P. de leenHeer. 1991. Liquid 
chromatographic determination of efficacy of incorporation of 
Trimethoprim and Sulfamethoxazole in Brine Shrimp (Artemia spp.). 
Used for prophylactic chemotherapy of fish. Antimicrobial Agents 
and Chemotherapy 35 (12): 2486-2489.
roque, A., j.F. TurnBull & A. goMez-gil. 1998. Delivery of bioencap-
sulated oxytetracycline to the marine shrimp Penaeus monodon. 
Journal of the World Aquaculture Society 29: 249-251.
sorgeloos, P. P. lAVens, P. léger; P. TACkAerT & w. VersiCHele. 1986. 
Manual for the culture and use of brine shrimp Artemia in aquacultu-
60 Castro-Mejia, G., et al.
re. Manual prepared for the Belgian Administration for Development 
Cooperation and the Food and Agriculture Organization of the United 
Nations. Artemia Reference Center. Faculty of Agriculture, State 
University of Ghent, Belgium. 319 p.
TourAki, M., P. rigAs, P. PergAnTAs, T. ABATzoPoulos & C. kAsTriTsis. 
1991. Optimizing bioencapsulation of the antibiotics trimethoprim 
and sulfametroxazole in Artemia nauplii. In: Lavens, P., Sorgeloos 
P.M., Jaspers, E. & F. Ollevier (Eds.). Larvi. Fish and Crustacean 
Larviculture Symposium. Special Publication No. 15. European 
Aquaculture Society, Ghent, Belgium, pp. 415-417.
TourAki, M., s. MourelATos, g. kArAMAnlidou, s. kAlAiTzoPoulou 
& C. kAsTriTsis. 1996. Bioencapsulation of chemotherapeutics in 
Artemia as a means of prevention and treatment in infection disea-
ses of marine fish fry. Aquaculture Engineering 15: 133-147.
TourAki, M., i. nioPAs & C. kAsTriTsis. 1999. Bioaccumulation of 
trimethoprim, sulfamethoxazole and N-Acetyl-Sulfamethoxazole in 
Artemia nauplii and residual kinetics in seabass larvae after repea-
ted oral dosing of medicated nauplii. Aquaculture 175: 15-30.
TrusT, T.j. 1986. Pathogenesis of infectious diseases of fish. Annual 
Review of Microbiology 40: 479-502.
VerPrAeT, r., M. CHAir, P. léger, H. nelis, P. sorgeloos & A. de 
leenHeer. 1992. Live-food mediated drug delivery as a tool of dis-
ease treatment in larviculture. The enrichment of therapeutics in 
rotifers and Artemia nauplii. Aquaculture Engineering 11: 133-139.
wilson, j. A. 1989. Fundamentos de Fisiología Animal. Limusa y 
McMillan, México, 984 pp.
Recibido: 09 de febrero de 2006.
Aceptado: 19 de octubre de 2006.
